C5 and neoplasm: In order to assess the differences between LGG patients with different risk values and immunophenotyping, according to the distribution of immunophenotyping of different types of tumor samples in the TCGA database, we combined inflammatory (Immune C3), lymphocyte-depleted (Immune C4), and immunologically quiet (Immune C5) responses.